BioStock: Spago Nanomedical on the progress with Tumorad

This week, Lund-based Spago Nanomedical presented positive preclinical data in its cancer treatment project Tumorad. After treatment with the candidate ¹⁷⁷Lu-SN201, a significant reduction in tumour growth was shown in a colorectal cancer model. In addition, the survival was extended by 39 per cent compared to the control group. BioStock contacted CEO Mats Hansen for a comment on the development work with Tumorad.

Read the interview with Spago Nanomedical's CEO Mats Hansen at biostock.se:

https://www.biostock.se/en/2022/01/spago-nanomedical-on-the-progress-with-tumorad/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/